TANDEM DIABETES CARE INC

TNDM - CIK 0001438133

Market cap$1.11 B

Rank#2566

SEC filings1,234

TANDEM DIABETES CARE INC trades as TNDM and has a market capitalization of $1.11 B, making it the #2566 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.01B, up 7.9% from the prior year and net income of -$204.70M. This page tracks TANDEM DIABETES CARE INC through 1,234 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$1.01BFY 2025

Net income (latest FY)-$204.70MFY 2025

Operating cash flow (latest FY)-$9.72MFY 2025

Total assets (latest FY)$881.11MFY 2025

Gross margin53.8%latest FY

Net margin-20.2%latest FY

Financial performance

Over the last 9 fiscal years TANDEM DIABETES CARE INC's revenue grew from $84.25M to $1.01B, a compound annual growth rate of 31.9%. Net profit margin expanded from -99.0% to -20.2% over the same period - every figure below comes from the company's audited annual filings.

TNDM annual revenueView details

Key statistics

Market cap: $1.11 B
Share price (derived)market cap / shares outstanding: $16.18
EPS (diluted)FY 2025: $-3.04
Shares outstandingas of 2026-05-04: 0.07B
Total equityas of 2026-03-31: $132.40M
Return on equity: -154.6%
Long-term debtas of 2026-03-31: $601.77M
Cash & equivalentsas of 2026-03-31: $179.32M

Latest filings

Filing	Type	Filed
Insider trade	4	2026-05-22
Insider trade	4	2026-05-22
Insider trade	4	2026-05-22
Insider trade	4	2026-05-22
Insider trade	4	2026-05-22
Insider trade	4	2026-05-22
Insider trade	4	2026-05-22
Insider trade	4	2026-05-22

Browse the full filing history (1,234 filings)

Recent press releases

Tandem Diabetes Care Announces First Quarter 2026 Financial Results2026-05-07
Tandem Diabetes Care Announces First Quarter 2026 Financial Results | Tandem Diabetes Care
Tandem Diabetes Care Announces Upcoming Conference Presentations2026-04-29
Tandem Diabetes Care Announces Upcoming Conference Presentations | Tandem Diabetes Care
Tandem Diabetes Care’s Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes2026-04-27
Tandem Diabetes Care’s Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes | Tandem Diabetes Care
Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 20262026-04-02
A live webcast of the call will be available on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section. To access the call by phone, please use this link ( https://register-conf.media-server.com/register/BI870b8c6fdaae4b6d982fb59187bc9470 ) and you will be provided with dial-in details, including a personal pin.
Tandem Mobi Now Compatible with Android Smartphones2026-03-04
Tandem Mobi Now Compatible with Android Smartphones | Tandem Diabetes Care

Similar companies

The largest companies sharing TANDEM DIABETES CARE INC's SEC industry classification (surgical & medical instruments & apparatus).

SYKStryker Corporation$117.82 B TNDM vs SYK

MMM3M Company$81.87 B TNDM vs MMM

BSXBoston Scientific Corporation$71.33 B TNDM vs BSX

MDLNMedline Inc.$49.12 B TNDM vs MDLN

BDXBecton, Dickinson and Company$41.03 B TNDM vs BDX

Frequently asked questions

What is TANDEM DIABETES CARE INC's market cap?

TANDEM DIABETES CARE INC (TNDM) has a market capitalization of $1.11 B as of 2026-06-10, ranking #2566 among US-listed companies.

How much revenue does TANDEM DIABETES CARE INC make?

TANDEM DIABETES CARE INC reported revenue of $1.01B for fiscal year 2025, an increase of 7.9% year over year.

Is TANDEM DIABETES CARE INC profitable?

In its latest fiscal year TANDEM DIABETES CARE INC reported a net loss of $204.70M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.